Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 14.01.2019 1 Am J Clin Oncol 1 Ann Oncol 2 Ann Surg 2 Ann Thorac Surg 2 Anticancer Res 6 BMC Cancer 1 BMJ 1 Cancer 1 Cancer Res 2 Chest 2 Clin Cancer Res 1 Clin Exp Metastasis 2 Clin Lung Cancer 2 Eur J Cardiothorac Surg 4 Int J Cancer 2 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Thorac Oncol 1 Lancet Respir Med 1 Lung Cancer 3 Oncol Rep 3 PLoS One 1 Science 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. MOORE S, Leung B, Wu J, Ho C, et al
   Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.
   Am J Clin Oncol. 2019 Jan 2. doi: 10.1097/COC.0000000000000513.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
   Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
   Ann Oncol. 2019 Jan 8. pii: 5280724. doi: 10.1093.
   PubMed     Text format    
   
   

   
   Ann Surg

3. REHMANI S, Bhora F, Flores R
   Robotic Lung Cancer Surgery: A Missed Opportunity and a Faulty Conclusion.
   Ann Surg. 2018;267:e34.
   PubMed     Text format    
   
   
4. PARK BJ
   Reply to Letter: "Long-term Survival Based on the Surgical Approach to Lobectomy for Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy".
   Ann Surg. 2018;267:e34-e35.
   PubMed     Text format    
   
   

   
   Ann Thorac Surg

5. FUKUI M, Suzuki K, Matsunaga T, Oh S, et al
   The Importance of Smoking Cessation on Surgical Outcome in Primary Lung Cancer.
   Ann Thorac Surg. 2019 Jan 2. pii: S0003-4975(18)31871.
   PubMed     Text format     Abstract available
   
   
6. WEKSLER B
   Radiotherapy in Patients with Clinical N0, Pathologic N2 Non-Small Cell Lung Cancer After Complete Resection.
   Ann Thorac Surg. 2019 Jan 2. pii: S0003-4975(18)31875.
   PubMed     Text format    
   
   

   
   Anticancer Res

7. KAIRA K, Kamiyoshihara M, Kawashima O, Endoh H, et al
   Prognostic Impact of beta2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma.
   Anticancer Res. 2019;39:395-403.
   PubMed     Text format     Abstract available
   
   
8. CHU CN, Wu KC, Chung WS, Zheng LC, et al
   Etomidate Suppresses Invasion and Migration of Human A549 Lung Adenocarcinoma Cells.
   Anticancer Res. 2019;39:215-223.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. KORDOWSKI F, Kolarova J, Schafmayer C, Buch S, et al
   Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
   BMC Cancer. 2018;18:796.
   PubMed     Text format     Abstract available
   
   
10. WERUTSKY G, Hochhegger B, Lopes de Figueiredo Pinto JA, Martinez-Mesa J, et al
    PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).
    BMC Cancer. 2019;19:5.
    PubMed     Text format     Abstract available
    
    
11. WU Z, Wang Q, Wu C, Zhan T, et al
    Three-port single-intercostal versus multiple-intercostal thoracoscopic lobectomy for the treatment of lung cancer: a propensity-matched analysis.
    BMC Cancer. 2019;19:8.
    PubMed     Text format     Abstract available
    
    
12. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Text format     Abstract available
    
    
13. YAN S, Sun R, Wu S, Jin T, et al
    Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study.
    BMC Cancer. 2019;19:35.
    PubMed     Text format     Abstract available
    
    
14. CASSIM S, Chepulis L, Keenan R, Kidd J, et al
    Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review.
    BMC Cancer. 2019;19:25.
    PubMed     Text format     Abstract available
    
    

    
    BMJ

15. MULLER DC, Larose TL, Hodge A, Guida F, et al
    Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium.
    BMJ. 2019;364:k4981.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

16. DELLA CORTE CM, Gay CM, Byers LA
    Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31863.
    PubMed     Text format    
    
    

    
    Cancer Res

17. FILIPCZAK PT, Leng S, Tellez CS, Do KC, et al
    p53-suppressed oncogene TET1 prevents cellular aging in lung cancer.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-1234.
    PubMed     Text format     Abstract available
    
    

    
    Chest

18. TANNER NT, Banas E, Yeager D, Dai L, et al
    In-person and Telephonic Shared Decision-making Visits for People Considering Lung Cancer Screening: An Assessment of Decision Quality.
    Chest. 2019;155:236-238.
    PubMed     Text format    
    
    
19. DETTERBECK FC
    Are We There Yet?: Understanding Differences in Rates of Resection of Clinical Stage I Lung Cancer.
    Chest. 2019;155:7-8.
    PubMed     Text format    
    
    

    
    Clin Cancer Res

20. THATCHER N, Goldschmidt JH, Thomas M, Schenker M, et al
    Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2702.
    PubMed     Text format     Abstract available
    
    
21. CHEN X, Chang CW, Spoerke JM, Yoh K, et al
    Low-Pass Whole-Genome Sequencing of Circulating Cell-Free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-1593.
    PubMed     Text format     Abstract available
    
    

    
    Clin Exp Metastasis

22. CHEN WG, Sun J, Shen WW, Yang SZ, et al
    Sema4D expression and secretion are increased by HIF-1alpha and inhibit osteogenesis in bone metastases of lung cancer.
    Clin Exp Metastasis. 2019 Jan 7. pii: 10.1007/s10585-018-9951.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

23. SUZUKI R, Wei X, Allen PK, Cox JD, et al
    Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
    Clin Lung Cancer. 2018 Nov 29. pii: S1525-7304(18)30309.
    PubMed     Text format     Abstract available
    
    
24. AKAMATSU H, Teraoka S, Koh Y, Yamanaka T, et al
    A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L).
    Clin Lung Cancer. 2018 Dec 11. pii: S1525-7304(18)30325.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cardiothorac Surg

25. AIGNER C
    To be or not to be central-does this really matter?
    Eur J Cardiothorac Surg. 2018;54:141.
    PubMed     Text format    
    
    
26. RESCIGNO G, Hogan J, Strong P
    The ideal use of dogs in medicine.
    Eur J Cardiothorac Surg. 2018;54:197.
    PubMed     Text format    
    
    

    
    Int J Cancer

27. YU Y, Jin H, Xu J, Gu J, et al
    XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIbeta mRNA stability.
    Int J Cancer. 2017 Dec 18. doi: 10.1002/ijc.31223.
    PubMed     Text format     Abstract available
    
    
28. WU Y, Ju Q, Jia K, Yu J, et al
    Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Int J Cancer. 2018;143:45-51.
    PubMed     Text format     Abstract available
    
    
29. XIE J, Shen K, Lenchine RV, Gethings LA, et al
    Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
    Int J Cancer. 2018;142:1865-1877.
    PubMed     Text format     Abstract available
    
    
30. TAN J, Fu L, Chen H, Guan J, et al
    Association study of genetic variation in the autophagy lysosome pathway genes and risk of eight kinds of cancers.
    Int J Cancer. 2018;143:80-87.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

31. ABDELBASET-ISMAIL A, Pedziwiatr D, Schneider G, Niklinski J, et al
    [Corrigendum] Pituitary sex hormones enhance the prometastatic potential of human lung cancer cells by downregulating the intracellular expression of heme oxygenase1.
    Int J Oncol. 2019 Jan 3. doi: 10.3892/ijo.2019.4670.
    PubMed     Text format     Abstract available
    
    
32. SANG Y, Sun L, Wu Y, Yuan W, et al
    Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
    Int J Oncol. 2019 Jan 9. doi: 10.3892/ijo.2019.4682.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

33. ZHANG TW, Snir J, Boldt RG, Rodrigues GB, et al
    Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature.
    Int J Radiat Oncol Biol Phys. 2019 Jan 7. pii: S0360-3016(18)34226.
    PubMed     Text format     Abstract available
    
    
34. VANDERSTRAETEN B, Goddeeris B, Vandecasteele K, van Eijkeren M, et al
    Automated Instead of Manual Treatment Planning? A Plan Comparison Based on Dose-Volume Statistics and Clinical Preference.
    Int J Radiat Oncol Biol Phys. 2018;102:443-450.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

35. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    J Clin Oncol. 2019 Jan 8:JCO1800149. doi: 10.1200/JCO.18.00149.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

36. LU S, Yu Y, Li Z, Yu R, et al
    Brief Report: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
    J Thorac Oncol. 2019 Jan 2. pii: S1556-0864(18)33515.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Respir Med

37. THE LANCET RESPIRATORY MEDICIN
    Lung cancer screening in Europe: hurdles to overcome.
    Lancet Respir Med. 2018;6:885.
    PubMed     Text format    
    
    

    
    Lung Cancer

38. LIN YT, Chu CY
    Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer.
    Lung Cancer. 2018 Dec 31. pii: S0169-5002(18)30730.
    PubMed     Text format    
    
    

    
    Oncol Rep

39. ZHAI Y, Wei R, Sha S, Lin C, et al
    Effect of NELL1 on lung cancer stemlike cell differentiation.
    Oncol Rep. 2019 Jan 3. doi: 10.3892/or.2019.6954.
    PubMed     Text format     Abstract available
    
    
40. CHEN S, Zhao Y, Shen F, Long D, et al
    Introduction of exogenous wildtype p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factorkappaB in nonsmall cell lung cancer NCIH1299 cells.
    Oncol Rep. 2019 Jan 10. doi: 10.3892/or.2019.6964.
    PubMed     Text format     Abstract available
    
    
41. LIU W, Liang Y, Chan Q, Jiang L, et al
    CX3CL1 promotes lung cancer cell migration and invasion via the Src/focal adhesion kinase signaling pathway.
    Oncol Rep. 2019 Jan 9. doi: 10.3892/or.2019.6957.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

42. OH DK, Ji WJ, Kim WS, Choi CM, et al
    Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice.
    PLoS One. 2019;14:e0210225.
    PubMed     Text format     Abstract available
    
    
43. CHOUAID C, Salaun M, Gounant V, Febvre M, et al
    Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB).
    PLoS One. 2019;14:e0208992.
    PubMed     Text format     Abstract available
    
    
44. LI Y, Appius A, Pattipaka T, Feyereislova A, et al
    Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
    PLoS One. 2019;14:e0209709.
    PubMed     Text format     Abstract available
    
    

    
    Science

45. PARK JW, Lee JK, Sheu KM, Wang L, et al
    Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.
    Science. 2018;362:91-95.
    PubMed     Text format     Abstract available
    
    

    
    Thorax

46. KIM CH, Jeong JS, Kim SR, Lee YC, et al
    Endobronchial epithelial-myoepithelial carcinoma of the lung.
    Thorax. 2018;73:593-594.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: